Posts by Sandra Ansanay-Alex
The GenPK Project Receives CHF 3,5 millions from FNS
The Jules Gonin Eye Hospital, the CHUV and the University of Lausanne are to study the genomes of 12,000 people from highly consanguineous families in Pakistan in order to improve the detection of risks associated with developing rare diseases. The Swiss National Science Foundation has awarded a funding of CHF 3,494,000 to Dr Muhammad Ansar,…
Read MoreInvestors & Innovators × JLABS Accelerator
On Wednesday, May 13th, at Campus Biotech Geneva, BioAlps welcomed Elena Fernandez Kleinlein and Michael Huebner of Johnson & Johnson Innovation / JLABS Accelerator for an afternoon of close-up encounters with some of the most promising neurotech and biotech ventures emerging from the Swiss Health Valley. The visit followed a morning at Biopole in Lausanne…
Read MoreDr Andrea Pfeifer Retires From AC Immune
AC Immune SA, a Lausanne-based clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, announces that Dr Andrea Pfeifer has decided to retire from her role as Chief Executive Officer (CEO) of AC Immune, after 23 years of tenure, at the upcoming Annual General Meeting (AGM) to spend more time with her family. Dr Pfeifer…
Read MoreRobert Wenner Prize: Two Cancer Researchers Honoured
The Robert Wenner Prize, which recognises scientists in the field of cancer research, is being awarded this year for the first time to two female researchers: Professor Michal Bassani-Sternberg (University of Lausanne/CHUV) and Professor Camilla Jandus (University of Geneva). The Swiss Cancer League is honouring both for their pioneering work in the field of immunotherapy.…
Read MoreMindmaze joins forces with Vibra Healthcare to bring its neurotherapies to the United States
After first announcing a partnership in 2022, the Lausanne-based neurotech company aims to speed up the launch of its digital neurological rehabilitation solutions on the US market using the Vibra Healthcare network and know-how. MindMaze Therapeutics, a pioneer in advanced neurotherapeutic technologies, and Vibra Healthcare, a leading provider of neurological care and rehabilitation services, announced…
Read MoreSDSC and Canton of Vaud Support Bewe Lab and Perivision
Bewe Lab and Perivision are among the four companies selected by Canton de Vaud and the Swiss Data Science Center (SDSC) to join a new programme to help companies boost their projects with artificial intelligence and data science. The goal is to establish artificial intelligence as a key part of the Vaud economy. Bewe Lab:…
Read MoreImmitra Bio Receives a CHF 150,000 Gebert Rüf Stiftung InnoBooster Grant
Geneva-based startup Immitra Bio has been selected as one of the latest winners of the InnoBooster programme, supported by the Gebert Rüf Stiftung. This CHF 150,000 grant will be used to build a scalable in-vivo gene-editing platform to make genetic therapies accessible to all patients, regardless of where they live or their financial means. Founded…
Read MoreHAS Healthcare Advanced Synthesis Group Announces Strategic Investments in Biodelphis Therapeutics
HAS Healthcare Advanced Synthesis (Ticino) and Biodelphis Therapeutics (Vaud) announced the signing of a strategic agreement to support the development and GMP manufacturing of Antibody Protease Inhibitor Conjugates, an emerging class of targeted therapeutics designed to selectively inhibit disease‑driving proteases. This collaboration combines HAS Group long‑standing expertise in complex bioconjugation, process development, and clinical‑grade manufacturing…
Read MoreMoonlight AI AG Raises $3.3M Seed Round
Moonlight AI AG, a Swiss startup building image analysis software for clinical-grade diagnostics, has closed a $3.3 million USD Seed round. The investment was co-led by Lotus One Investment (Singapore), VP Venture Partners (Switzerland), and MEDIN Fund (Tunisia), with participation from N&V Capital (Liechtenstein) and existing investor QAI Ventures (Switzerland). Turning routine slide images into…
Read MoreSwiss Biotech on the Rise: Strong Momentum in 2025
Switzerland’s biotech sector continues to demonstrate remarkable resilience and growth, even in a complex global environment. According to the latest Swiss Biotech Report 2026, the industry reached new heights in 2025—both in terms of revenue and investment—further strengthening the country’s position as a global life sciences powerhouse. Record performance in a challenging context The numbers…
Read More